Log on / register
Feedback | Support | My details
Open AccessResearch article

Obliteration of radical cavities with autogenous cortical bone; long-term results

Akram M Abdel-Rahman1,2 email, Matti Pietola2 email, Teemu J Kinnari2 email, Hans Ramsay2 email, Jussi Jero2 email and Antti A Aarnisalo2 email

Audiology Unit, Dept. of Otorhinolaryngology, Mansoura Univ., Mansoura, Egypt

Dept. of Otorhinolaryngology, Univ. of Helsinki, Helsinki, Finland

author email corresponding author email

BMC Ear, Nose and Throat Disorders 2008, 8:4doi:10.1186/1472-6815-8-4

Published: 29 July 2008

Abstract

Background

To evaluate the long-term surgical outcome(s) in patients who have undergone canal-wall-down operation with mastoid and epitympanic obliteration using autologous cortical bone chips, bone pate and meatally-based musculoperiosteal flap technique.

Method

Retrospective evaluation of seventy patients operated during 1986–1991 due to a cholesteatoma. An otomicroscopy was performed to evaluate the postoperative outer ear canal configuration with a modified Likert scale (1 – 4). The outer ear canal physical volume was assessed by tympanometry. The hearing outcome and a patient-filled questionnaire were also analyzed.

Results

The posterior wall results were 1.8 (± 0.9 SD) and the attic region 1.8 (± 0.9 SD) (ns., p > 0.05). These values show either no cavity formation or minor formation of a cavity, with a good functional result. The mean volume of the operated ear canal was 1.7 (± 0.5 SD) ml. The volume of the contralateral ear canal was 1.2 (± 0.3 SD) ml (*** p < 0.0001). A comparison of the current mean ABG to the preoperative mean ABG and to the ABG at one-year postoperatively, 5-years postoperatively or 10-years postoperatively showed no statistical significance (p > 0.05).

Conclusion

ABG does not significantly change in the long-term. The configuration of the cavity tends to change, however, the obliteration material is stable in the long-term and clinically significant cavitation rarely occurs.


© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.